Driver network as a biomarker: systematic integration and network modeling of multi-omics data to derive driver signaling pathways for drug combination prediction

Abstract Motivation Drug combinations that simultaneously suppress multiple cancer driver signaling pathways increase therapeutic options and may reduce drug resistance. We have developed a computational systems biology tool, DrugComboExplorer, to identify driver signaling pathways and predict synergistic drug combinations by integrating the knowledge embedded in vast amounts of available pharmacogenomics and omics data. Results This tool generates driver signaling networks by processing DNA sequencing, gene copy number, DNA methylation and RNA-seq data from individual cancer patients using an integrated pipeline of algorithms, including bootstrap aggregating-based Markov random field, weighted co-expression network analysis and supervised regulatory network learning. It uses a systems pharmacology approach to infer the combinatorial drug efficacies and synergy mechanisms through drug functional module-induced regulation of target expression analysis. Application of our tool on diffuse large B-cell lymphoma and prostate cancer demonstrated how synergistic drug combinations can be discovered to inhibit multiple driver signaling pathways. Compared with existing computational approaches, DrugComboExplorer had higher prediction accuracy based on in vitro experimental validation and probability concordance index. These results demonstrate that our network-based drug efficacy screening approach can reliably prioritize synergistic drug combinations for cancer and uncover potential mechanisms of drug synergy, warranting further studies in individual cancer patients to derive personalized treatment plans. Availability and implementation DrugComboExplorer is available at https://github.com/Roosevelt-PKU/drugcombinationprediction. Supplementary information Supplementary data are available at Bioinformatics online.

[1]  J. Greene,et al.  Combination drugs--hype, harm, and hope. , 2011, The New England journal of medicine.

[2]  Matthew West,et al.  Bayesian factor regression models in the''large p , 2003 .

[3]  K. Polyak,et al.  Targeting the missing links for cancer therapy , 2011, Nature Medicine.

[4]  X-S Zhang,et al.  Predicting cooperative drug effects through the quantitative cellular profiling of response to individual drugs , 2014, CPT: pharmacometrics & systems pharmacology.

[5]  C. Sander,et al.  Models from experiments: combinatorial drug perturbations of cancer cells , 2008, Molecular systems biology.

[6]  Kyoung Mii Park,et al.  CDA: Combinatorial Drug Discovery Using Transcriptional Response Modules , 2012, PloS one.

[7]  Tao Xu,et al.  Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways , 2013, PLoS Comput. Biol..

[8]  M. Hung,et al.  Signaling cross-talk in the resistance to HER family receptor targeted therapy , 2014, Oncogene.

[9]  V. Hirsh.  The Treatment of Metastatic Non-Small Cell Lung Cancer in a New Era of Personalized Medicine , 2015, Front. Oncol..

[10]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[11]  Matteo Benelli,et al.  Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.

[12]  M. West,et al.  High-Dimensional Sparse Factor Modeling: Applications in Gene Expression Genomics , 2008, Journal of the American Statistical Association.

[13]  Yang Xie,et al.  A community computational challenge to predict the activity of pairs of compounds Citation , 2015 .

[14]  Delbert Dueck,et al.  Clustering by Passing Messages Between Data Points , 2007, Science.

[15]  G. Getz,et al.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.

[16]  Yiling Lu,et al.  Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. , 2010, Cancer research.

[17]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[18]  Xin Chen,et al.  DCDB: Drug combination database , 2010, Bioinform..

[19]  Tyler J. VanderWeele,et al.  Estimating measures of interaction on an additive scale for preventive exposures , 2011, European Journal of Epidemiology.

[20]  Alan F. Scott,et al.  Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders , 2002, Nucleic Acids Res..

[21]  Xing-Ming Zhao,et al.  Prediction of Drug Combinations by Integrating Molecular and Pharmacological Data , 2011, PLoS Comput. Biol..

[22]  P. Sanseau,et al.  Systematic prediction of drug combinations based on clinical side-effects , 2014, Scientific Reports.

[23]  Andreas Bender,et al.  DeepSynergy: predicting anti-cancer drug synergy with Deep Learning , 2017, Bioinform..

[24]  STC Wong,et al.  DIGRE: Drug-Induced Genomic Residual Effect Model for Successful Prediction of Multidrug Effects , 2015, CPT: pharmacometrics & systems pharmacology.

[25]  Damian Szklarczyk,et al.  STITCH 3: zooming in on protein–chemical interactions , 2011, Nucleic Acids Res..

[26]  René Bernards,et al.  A Missing Link in Genotype-Directed Cancer Therapy , 2012, Cell.

[27]  P. Jänne,et al.  Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[28]  Yi-Cheng Zhang,et al.  Solving the apparent diversity-accuracy dilemma of recommender systems , 2008, Proceedings of the National Academy of Sciences.

[29]  Tom Misteli,et al.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.

[30]  J. Reynolds,et al.  Overexpression of MMP-9 Contributes to Invasiveness of Prostate Cancer Cell Line LNCaP , 2011, Immunological investigations.

[31]  Mark R. Green,et al.  Targeting targeted therapy. , 2004, The New England journal of medicine.

[32]  H. Hieronymus,et al.  FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR , 2011, Nature.

[33]  Luca Toschi,et al.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. , 2010, Cancer cell.

[34]  H. Ellis,et al.  Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma , 2015, Front. Oncol..

[35]  D. A. Stein,et al.  A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity , 2003, Cancer Gene Therapy.

[36]  S. Nelson,et al.  Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance , 2012, Nature Communications.

[37]  Jean-Philippe Vert,et al.  SIRENE: supervised inference of regulatory networks , 2008, ECCB.

[38]  P. Edwards,et al.  Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells , 2011, Science Signaling.

[39]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[40]  B. Chan,et al.  Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. , 2015, Translational lung cancer research.

[41]  David S. Wishart,et al.  DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..

[42]  X. Chen,et al.  TTD: Therapeutic Target Database , 2002, Nucleic Acids Res..

[43]  Young Lim Choi,et al.  EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. , 2010, The New England journal of medicine.

[44]  B. Al-Lazikani,et al.  Combinatorial drug therapy for cancer in the post-genomic era , 2012, Nature Biotechnology.

[45]  Daniel B. Mark,et al.  TUTORIAL IN BIOSTATISTICS MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS , 1996 .